Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s proBNP

This article was originally published in The Gray Sheet

Executive Summary

The firm's Elecsys cardiac marker assay is the first natriuretic peptide test cleared by FDA for risk assessment of cardiac events for people with stable coronary artery disease, Roche announces Jan. 3. "Since this is an early marker of cardiac involvement in these disease processes, once a person is identified to be at cardiac risk, they can work with their physician to determine the best treatment and therapy early on," Roche Diagnostics Chief Medical Officer Mike Samoszuk said Jan. 3. ProBNP assays, also available on Dade Behring's Stratus system, have been cleared for aiding congestive heart failure (CHF) diagnosis and as a risk marker for patients with acute coronary syndrome and CHF...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT023087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel